Development and Validation of an m6A RNA Methylation Regulator-Based Signature for Prognostic Prediction in Cervical Squamous Cell Carcinoma

Background: Cervical squamous cell carcinoma (CESC) is one of the most common causes of cancer-related death worldwide. N6-methyladenosine (m6A) plays an important role in various cellular responses by regulating mRNA biology. This study aimed to develop and validate an m6A RNA methylation regulator...

Full description

Bibliographic Details
Main Authors: Jingxin Pan, Lichao Xu, Hongda Pan
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01444/full
_version_ 1818204723064340480
author Jingxin Pan
Lichao Xu
Lichao Xu
Hongda Pan
author_facet Jingxin Pan
Lichao Xu
Lichao Xu
Hongda Pan
author_sort Jingxin Pan
collection DOAJ
description Background: Cervical squamous cell carcinoma (CESC) is one of the most common causes of cancer-related death worldwide. N6-methyladenosine (m6A) plays an important role in various cellular responses by regulating mRNA biology. This study aimed to develop and validate an m6A RNA methylation regulator-based signature for prognostic prediction in CESC.Methods: Clinical and survival data as well as RNA sequencing data of 13 m6A RNA methylation regulators were obtained from The Cancer Genome Atlas (TCGA) CESC database. Consensus clustering was performed to identify different CESC clusters based on the differential expression of the regulators. LASSO Cox regression analysis was used to generate a prognostic signature based on m6A RNA methylation regulator expression. The effect of the signature was further explored by univariate and multivariate Cox analyses.Results: Four regulators (RBM15, METTL3, FTO, and YTHDF2) were identified to be aberrantly expressed in CESC tissues. A prognostic signature that includes ZC3H13, YTHDC1, and YTHDF1 was developed, which can act as an independent prognostic indicator. Significant differences of survival rate and clinicopathological features were found between the high- and low-risk groups. The results of bioinformatics analysis were then validated in the clinical CESC cohort by qRT-PCR and immunohistochemistry staining.Conclusion: In the present study, we developed and validated an m6A RNA methylation regulator-based prognostic signature, which might provide useful insights regarding the development and prognosis of CESC.
first_indexed 2024-12-12T03:45:46Z
format Article
id doaj.art-de6fb7b4598a4fd190ccc5db474797ce
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-12T03:45:46Z
publishDate 2020-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-de6fb7b4598a4fd190ccc5db474797ce2022-12-22T00:39:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-08-011010.3389/fonc.2020.01444544982Development and Validation of an m6A RNA Methylation Regulator-Based Signature for Prognostic Prediction in Cervical Squamous Cell CarcinomaJingxin Pan0Lichao Xu1Lichao Xu2Hongda Pan3Department of Internal Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, ChinaDepartment of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, ChinaBackground: Cervical squamous cell carcinoma (CESC) is one of the most common causes of cancer-related death worldwide. N6-methyladenosine (m6A) plays an important role in various cellular responses by regulating mRNA biology. This study aimed to develop and validate an m6A RNA methylation regulator-based signature for prognostic prediction in CESC.Methods: Clinical and survival data as well as RNA sequencing data of 13 m6A RNA methylation regulators were obtained from The Cancer Genome Atlas (TCGA) CESC database. Consensus clustering was performed to identify different CESC clusters based on the differential expression of the regulators. LASSO Cox regression analysis was used to generate a prognostic signature based on m6A RNA methylation regulator expression. The effect of the signature was further explored by univariate and multivariate Cox analyses.Results: Four regulators (RBM15, METTL3, FTO, and YTHDF2) were identified to be aberrantly expressed in CESC tissues. A prognostic signature that includes ZC3H13, YTHDC1, and YTHDF1 was developed, which can act as an independent prognostic indicator. Significant differences of survival rate and clinicopathological features were found between the high- and low-risk groups. The results of bioinformatics analysis were then validated in the clinical CESC cohort by qRT-PCR and immunohistochemistry staining.Conclusion: In the present study, we developed and validated an m6A RNA methylation regulator-based prognostic signature, which might provide useful insights regarding the development and prognosis of CESC.https://www.frontiersin.org/article/10.3389/fonc.2020.01444/fullm6ARNA methylationcervical squamous cell carcinomaprognosisexperimental validation
spellingShingle Jingxin Pan
Lichao Xu
Lichao Xu
Hongda Pan
Development and Validation of an m6A RNA Methylation Regulator-Based Signature for Prognostic Prediction in Cervical Squamous Cell Carcinoma
Frontiers in Oncology
m6A
RNA methylation
cervical squamous cell carcinoma
prognosis
experimental validation
title Development and Validation of an m6A RNA Methylation Regulator-Based Signature for Prognostic Prediction in Cervical Squamous Cell Carcinoma
title_full Development and Validation of an m6A RNA Methylation Regulator-Based Signature for Prognostic Prediction in Cervical Squamous Cell Carcinoma
title_fullStr Development and Validation of an m6A RNA Methylation Regulator-Based Signature for Prognostic Prediction in Cervical Squamous Cell Carcinoma
title_full_unstemmed Development and Validation of an m6A RNA Methylation Regulator-Based Signature for Prognostic Prediction in Cervical Squamous Cell Carcinoma
title_short Development and Validation of an m6A RNA Methylation Regulator-Based Signature for Prognostic Prediction in Cervical Squamous Cell Carcinoma
title_sort development and validation of an m6a rna methylation regulator based signature for prognostic prediction in cervical squamous cell carcinoma
topic m6A
RNA methylation
cervical squamous cell carcinoma
prognosis
experimental validation
url https://www.frontiersin.org/article/10.3389/fonc.2020.01444/full
work_keys_str_mv AT jingxinpan developmentandvalidationofanm6arnamethylationregulatorbasedsignatureforprognosticpredictionincervicalsquamouscellcarcinoma
AT lichaoxu developmentandvalidationofanm6arnamethylationregulatorbasedsignatureforprognosticpredictionincervicalsquamouscellcarcinoma
AT lichaoxu developmentandvalidationofanm6arnamethylationregulatorbasedsignatureforprognosticpredictionincervicalsquamouscellcarcinoma
AT hongdapan developmentandvalidationofanm6arnamethylationregulatorbasedsignatureforprognosticpredictionincervicalsquamouscellcarcinoma